决策辅助的可行性和有效性,以改善对外预防性乳房切除的决策:系统性审查
Ariana Naaseh1,2, Sophia X Tang1, Kim L Lipsey3
1Division of Surgical Oncology, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Annals of surgical oncology
|August 8, 2025
概括
对逆向预防性乳房切除术 (CPM) 的决策辅助工具 (DA) 显示了高患者满意度和知识增加. 需要进一步的研究来优化DA的设计和交付,以便在乳腺癌护理中共享决策.
科学领域:
- 在瘤学瘤学.
- 医疗决策的制定 医疗决策的制定
- 医疗保健服务研究 医疗服务研究
背景情况:
- 单侧乳腺癌的逆侧预防性乳房切除 (CPM) 率正在上升.
- 决策辅助工具 (DA) 可以促进共享决策.
- 本综述评估了DA在CPM决策中的可行性和有效性.
研究的目的:
- 系统地审查关于对逆向预防性乳房切除术 (CPM) 决策辅助的文献.
- 了解DA在改善CPM决策结果方面的可行性和有效性.
- 在这种情况下,确定DA的关键特征和最佳交付方法.
主要方法:
- 在六个数据库中进行系统的文献搜索,截至2024年4月.
- 包括对中低风险单边乳腺癌患者中CPM患者的患者DA的研究.
- 数据提取和质量评估 (GRADE) 由两名独立调查员进行.
主要成果:
- 包括6项研究 (2017-2021),其中4项专注于患者接受,两项专注于临床医生的参与.
- 在线 (50%),纸质 (33.3%) 或未知格式的DA交付.
- 报告显示,患者满意度高,知识增加,但缺乏关于最佳时间的共识.
结论:
- 进一步的研究对于开发和测试用于CPM决策的DA至关重要.
- 未来研究的关键领域包括信息平衡,内容,格式,时间和交付.
- 需要在较大人群中进行标准化测量,以评估DA对满意度,价值观,决策冲突和健康素养的影响.
更多相关视频
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
2.9K
06:03Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
6.7K
相关概念视频
Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455
Hazard Ratio
244
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
244
